

Doc Code: M865 or FAI.REQ.INTV

PTOL-413A (10-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**Applicant Initiated Interview Request Form**Application No.: 10/551,619
Examiner: WANG, Chang YuFirst Named Applicant: Paul Taylor Martin
Art Unit: 1649 Status of Application: Pending**Tentative Participants:**(1) Examiner ~~Chang~~ Wang (2) Examiner ~~Saul~~ Saoud
(3) Joseph R. Baker, Jr. (4) _____Proposed Date of Interview: 25 Jan. 2010 Proposed Time: 11 am (AM/PM)**Type of Interview Requested:**(1) ☒ Telephonic (2) ☐ Personal (3) ☐ Video ConferenceExhibit To Be Shown or Demonstrated: ☐ YES ☒ NO

If yes, provide brief description: _____

Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) <u>Rej</u>	<u>cls. 5-B and 11*12</u>	_____	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(2) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(3) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(4) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Continuation Sheet Attached☐ Proposed Amendment or Arguments Attached**Brief Description of Arguments to be Presented:**

Discuss possible examiner's amendment. Applicant to provide draft claims.

An interview was conducted on the above-identified application on 25 January 2010.**NOTE:** This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

/Joseph R. Baker, Jr./

Applicant/Applicant's Representative Signature

/Chang-Yu Wang/

Examiner/SPE Signature

Joseph R. Baker, Jr.

Typed/Printed Name of Applicant or Representative

40900

Registration Number, if applicable

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No. 00015-022US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	DRAFT CLAIMS
)	
Paul Taylor Martin)	Group Art Unit: 1649
)	
Application No.: 10/551,619)	Examiner: WANG, Chang Yu
)	
Filed: September 30, 2005)	Confirmation No.: 5898
)	
For: AMYLOID SPECIFIC PEPTIDES)	
AND USES THEREOF)	
)	
)	
)	
)	

Draft claims

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner Wang:

Thank you for your call of today. Attached are the draft claims for review. Support can be found at paragraph [0051] of the corresponding application publication 20070093415.

Respectfully submitted.

Very truly yours,

/Joseph R. Baker, Jr./

Reg. No. 40900

IN THE CLAIMS:

Please enter the attached listing of claims into the application. This listing of claims replaces all prior listing of claims in the application.

LISTING OF CLAIMS

1. (Previously Presented) An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:5.
2. (Previously Presented) An isolated polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO:5.
3. (Currently Amended) The isolated polypeptide of claim 1 or 2, wherein the cysteine residues are intramolecularly cross-linked via a disulfide bond.
4. (Cancelled)
5. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 15 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5, wherein the polypeptide interacts with the amyloid form of the A β peptide comprising the A β 1-40 peptide.
6. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 10 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5, wherein the polypeptide interacts with the amyloid form of the A β peptide comprising the A β 1-40 peptide.
7. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 5 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5, wherein the polypeptide interacts with the amyloid form of the A β peptide comprising the A β 1-40 peptide.

8. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 3 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5, wherein the polypeptide interacts with the amyloid form of the A β peptide comprising the A β 1-40 peptide.
9. (Previously Presented) The isolated polypeptide of claim 8, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4 or consists of the amino acid sequence of SEQ ID NO: 4.
10. (Currently Amended) The polypeptide of claims 1, 2 or 9, wherein the polypeptide binds to the amyloid form of the A β peptide comprising A β 1-40 peptide.
11. (Currently Amended) The polypeptide of claim[[s]] ~~1, 2 or 9~~, further comprising a ~~therapeutic or diagnostic compound~~ detectable label conjugated to the polypeptide, wherein the detectable label is selected from the group consisting of a fluorescent moiety, a chromogenic moiety, a luciferase, biotin and a radiolabel.
12. (Currently Amended) A composition ~~useful for treating or diagnosing Alzheimer's disease~~ for detecting A β peptide comprising A β 1-40 peptide in a mammal comprising a ~~pharmaceutically or diagnostically acceptable carrier and a therapeutically or diagnostically effective amount of a polypeptide of claim 11 as claimed in claims 1, 2 or 9.~~
13. (Withdrawn) A method of treating or diagnosing Alzheimer's disease in a mammal in need of such treatment, which comprises administering to the mammal a therapeutically- or diagnostically-effective amount of a composition as claimed in claim 12.
14. (Withdrawn) An isolated nucleic acid sequence encoding the polypeptide of claims 1, 2 or 9.
15. (Withdrawn) A vector comprising the nucleic acid sequence of claim 14.

16. (Withdrawn) The vector of claim 15, wherein the vector is an expression vector.
17. (Withdrawn) A host cell comprising the vector of claim 16.
18. (Withdrawn) The host cell of claim 17, wherein the host cell is a eukaryotic cell.
19. (Currently Amended) A hybrid molecule comprising: a) a peptide set forth in claim 1, 2 or 9, that specifically interacts with the amyloid form of the A β peptide comprising the A β 1-40 peptide; and b) a ~~scaffold molecule comprising a~~ diagnostic or therapeutic reagent.
- 20-23. (Cancelled)
24. (Withdrawn) A method of treating or diagnosing a neurodegenerative disease associated with aberrant plaque formation, the method comprising administering a hybrid molecule of claim 20 to a subject having, or predisposed to having, the disease.
25. (Withdrawn) The method as in claim 19, wherein said peptide binds specifically to the amyloid form of the A β ₁₋₄₀ peptide in plaques of Alzheimer's patients.
26. (Withdrawn) An anti-idiotypic antibody that specifically binds to a polypeptide of claim 1, 2 or 9.